View ValuationPhoenixBio 将来の成長Future 基準チェック /06現在、 PhoenixBioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長24.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 20Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025)Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.お知らせ • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026.お知らせ • May 10PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.お知らせ • Dec 02PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026分析記事 • Dec 01Is PhoenixBio (TSE:6190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 19Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025)Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.New Risk • Oct 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Market cap is less than US$100m (JP¥1.98b market cap, or US$13.0m).お知らせ • Sep 02PhoenixBio Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025PhoenixBio Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: JP¥4.69 (vs JP¥5.71 in 1Q 2025)First quarter 2026 results: EPS: JP¥4.69 (down from JP¥5.71 in 1Q 2025). Revenue: JP¥400.0m (down 11% from 1Q 2025). Net income: JP¥19.0m (down 17% from 1Q 2025). Profit margin: 4.8% (down from 5.1% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.分析記事 • Aug 05Is PhoenixBio (TSE:6190) A Risky Investment?TSE:6190 1 Year Share Price vs Fair Value Explore PhoenixBio's Fair Values from the Community and select yours Some say...お知らせ • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025PhoenixBio Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • May 21Full year 2025 earnings released: JP¥110 loss per share (vs JP¥6.88 profit in FY 2024)Full year 2025 results: JP¥110 loss per share (down from JP¥6.88 profit in FY 2024). Revenue: JP¥1.54b (down 10% from FY 2024). Net loss: JP¥445.0m (down JP¥471.0m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.お知らせ • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025.分析記事 • Apr 07PhoenixBio Co., Ltd. (TSE:6190) Looks Inexpensive After Falling 33% But Perhaps Not Attractive EnoughPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders won't be pleased to see that the share price has had a very rough month...New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.49b (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (JP¥1.49b market cap, or US$9.98m).お知らせ • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025PhoenixBio Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025分析記事 • Feb 19PhoenixBio Co., Ltd.'s (TSE:6190) Shares Bounce 31% But Its Business Still Trails The IndustryPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders would be excited to see that the share price has had a great month...Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.45 loss in 3Q 2024)Third quarter 2025 results: JP¥6.28 loss per share (further deteriorated from JP¥3.45 loss in 3Q 2024). Revenue: JP¥355.0m (down 21% from 3Q 2024). Net loss: JP¥26.0m (loss widened 100% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.42b market cap, or US$9.31m). Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change).お知らせ • Dec 03PhoenixBio Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025PhoenixBio Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025分析記事 • Nov 18PhoenixBio Co., Ltd.'s (TSE:6190) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.8x PhoenixBio Co., Ltd. ( TSE:6190 ) may be sending bullish signals at the...New Risk • Nov 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.46b (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.46b market cap, or US$9.39m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).お知らせ • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024PhoenixBio Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 18First quarter 2025 earnings released: EPS: JP¥5.71 (vs JP¥11.56 in 1Q 2024)First quarter 2025 results: EPS: JP¥5.71 (down from JP¥11.56 in 1Q 2024). Revenue: JP¥449.0m (up 2.3% from 1Q 2024). Net income: JP¥23.0m (down 45% from 1Q 2024). Profit margin: 5.1% (down from 9.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥467, the stock trades at a trailing P/E ratio of 72.9x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years.お知らせ • Jun 06PhoenixBio Co., Ltd. to Report Q1, 2025 Results on Aug 13, 2024PhoenixBio Co., Ltd. announced that they will report Q1, 2025 results on Aug 13, 2024Reported Earnings • May 21Full year 2024 earnings released: EPS: JP¥6.88 (vs JP¥145 in FY 2023)Full year 2024 results: EPS: JP¥6.88 (down from JP¥145 in FY 2023). Revenue: JP¥1.72b (down 19% from FY 2023). Net income: JP¥26.0m (down 95% from FY 2023). Profit margin: 1.5% (down from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • May 17PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024.お知らせ • Mar 03PhoenixBio Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024PhoenixBio Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024Reported Earnings • Feb 17Third quarter 2024 earnings released: JP¥3.45 loss per share (vs JP¥10.86 profit in 3Q 2023)Third quarter 2024 results: JP¥3.45 loss per share (down from JP¥10.86 profit in 3Q 2023). Revenue: JP¥447.0m (down 15% from 3Q 2023). Net loss: JP¥13.0m (down 135% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥1.92b market cap, or US$12.8m).お知らせ • Dec 07PhoenixBio Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024PhoenixBio Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024Reported Earnings • Nov 19Second quarter 2024 earnings released: JP¥4.05 loss per share (vs JP¥76.11 profit in 2Q 2023)Second quarter 2024 results: JP¥4.05 loss per share (down from JP¥76.11 profit in 2Q 2023). Revenue: JP¥442.0m (down 36% from 2Q 2023). Net loss: JP¥15.0m (down 106% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023PhoenixBio Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023Reported Earnings • Aug 17First quarter 2024 earnings released: EPS: JP¥11.56 (vs JP¥31.15 in 1Q 2023)First quarter 2024 results: EPS: JP¥11.56 (down from JP¥31.15 in 1Q 2023). Revenue: JP¥439.0m (down 1.3% from 1Q 2023). Net income: JP¥42.0m (down 59% from 1Q 2023). Profit margin: 9.6% (down from 23% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 14, 2023PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 14, 2023Reported Earnings • May 19Full year 2023 earnings released: EPS: JP¥145 (vs JP¥117 loss in FY 2022)Full year 2023 results: EPS: JP¥145 (up from JP¥117 loss in FY 2022). Revenue: JP¥2.12b (up 60% from FY 2022). Net income: JP¥493.0m (up JP¥880.0m from FY 2022). Profit margin: 23% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: JP¥10.86 (vs JP¥9.37 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥10.86 (up from JP¥9.37 loss in 3Q 2022). Revenue: JP¥525.0m (up 77% from 3Q 2022). Net income: JP¥37.0m (up JP¥68.0m from 3Q 2022). Profit margin: 7.0% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Dec 04PhoenixBio Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023PhoenixBio Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥76.11 (vs JP¥58.69 loss in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.11 (up from JP¥58.69 loss in 2Q 2022). Revenue: JP¥690.0m (up 273% from 2Q 2022). Net income: JP¥253.0m (up JP¥447.0m from 2Q 2022). Profit margin: 37% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 1 independent director (6 non-independent directors). Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022PhoenixBio Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥31.15 (vs JP¥19.46 in 1Q 2022)First quarter 2023 results: EPS: JP¥31.15 (up from JP¥19.46 in 1Q 2022). Revenue: JP¥445.0m (down 1.5% from 1Q 2022). Net income: JP¥103.0m (up 61% from 1Q 2022). Profit margin: 23% (up from 14% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022お知らせ • May 18PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022.Reported Earnings • May 17Full year 2022 earnings released: JP¥117 loss per share (vs JP¥73.60 loss in FY 2021)Full year 2022 results: JP¥117 loss per share (down from JP¥73.60 loss in FY 2021). Revenue: JP¥1.32b (up 31% from FY 2021). Net loss: JP¥387.0m (loss widened 63% from FY 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 08PhoenixBio Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022PhoenixBio Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥9.37 loss per share (up from JP¥24.33 loss in 3Q 2021). Revenue: JP¥296.0m (up 48% from 3Q 2021). Net loss: JP¥31.0m (loss narrowed 61% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥58.69 loss per share (vs JP¥44.41 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥185.0m (up 33% from 2Q 2021). Net loss: JP¥194.0m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • May 19Full year 2021 earnings released: JP¥73.60 loss per share (vs JP¥142 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: JP¥1.01b (down 23% from FY 2020). Net loss: JP¥238.0m (loss narrowed 43% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year.お知らせ • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021PhoenixBio Co., Ltd. announced that they will report fiscal year 2021 results on May 14, 2021Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥24.33 loss per share (vs JP¥9.54 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥200.0m (down 36% from 3Q 2020). Net loss: JP¥80.0m (loss widened 186% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Dec 22New 90-day low: JP¥582The company is down 20% from its price of JP¥727 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 18% over the same period.Is New 90 Day High Low • Dec 03New 90-day low: JP¥616The company is down 9.0% from its price of JP¥679 on 04 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period.お知らせ • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020PhoenixBio Co., Ltd. announced that they will report Q2, 2021 results on Nov 13, 2020お知らせ • Jun 20PhoenixBio Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020PhoenixBio Co., Ltd. announced that they will report Q1, 2021 results on Aug 12, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PhoenixBio は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:6190 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,5651255468N/A12/31/20251,598-205N/AN/AN/A9/30/20251,509-312-189-155N/A6/30/20251,492-452N/AN/AN/A3/31/20251,541-448-105-73N/A12/31/20241,530-138N/AN/AN/A9/30/20241,622-125-167-141N/A6/30/20241,7257N/AN/AN/A3/31/20241,71526-117-79N/A12/31/20231,792114N/AN/AN/A9/30/20231,870164176206N/A6/30/20232,118432N/AN/AN/A3/31/20232,124493265277N/A12/31/20222,051167N/AN/AN/A9/30/20221,822996164N/A6/30/20221,317-348N/AN/AN/A3/31/20221,324-3871016N/A12/31/20211,445-52N/AN/AN/A9/30/20211,349-101-90-32N/A6/30/20211,303-53N/AN/AN/A3/31/20211,013-238-283-101N/A12/31/2020978-578N/AN/AN/A9/30/20201,090-526-269-125N/A6/30/20201,184-458N/AN/AN/A3/31/20201,310-415-42-12N/A12/31/20191,231-220N/AN/AN/A9/30/20191,323-202N/A-36N/A6/30/20191,358-210N/AN/AN/A3/31/20191,228-297N/A-159N/A12/31/20181,087-303N/AN/AN/A9/30/20181,012-300N/A-156N/A6/30/2018937-297N/AN/AN/A3/31/2018902-270N/A-187N/A12/31/2017974-167N/AN/AN/A9/30/2017987-60N/A-64N/A6/30/20171,014-13N/AN/AN/A3/31/20171,228128N/A44N/A12/31/20161,317121N/AN/AN/A3/31/20161,217125N/A259N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6190の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6190の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6190の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6190の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6190の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6190の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 11:38終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PhoenixBio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥30.75 (vs JP¥111 loss in FY 2025)Full year 2026 results: EPS: JP¥30.75 (up from JP¥111 loss in FY 2025). Revenue: JP¥1.57b (up 1.6% from FY 2025). Net income: JP¥125.0m (up JP¥573.0m from FY 2025). Profit margin: 8.0% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
お知らせ • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2026.
お知らせ • May 10PhoenixBio Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026PhoenixBio Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥19.90 (vs JP¥6.28 loss in 3Q 2025)Third quarter 2026 results: EPS: JP¥19.90 (up from JP¥6.28 loss in 3Q 2025). Revenue: JP¥444.0m (up 25% from 3Q 2025). Net income: JP¥81.0m (up JP¥107.0m from 3Q 2025). Profit margin: 18% (up from net loss in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance.
お知らせ • Dec 02PhoenixBio Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026PhoenixBio Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026
分析記事 • Dec 01Is PhoenixBio (TSE:6190) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 19Second quarter 2026 earnings released: JP¥1.72 loss per share (vs JP¥36.30 loss in 2Q 2025)Second quarter 2026 results: JP¥1.72 loss per share (improved from JP¥36.30 loss in 2Q 2025). Revenue: JP¥356.0m (up 5.0% from 2Q 2025). Net loss: JP¥7.00m (loss narrowed 95% from 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.
New Risk • Oct 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Market cap is less than US$100m (JP¥1.98b market cap, or US$13.0m).
お知らせ • Sep 02PhoenixBio Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025PhoenixBio Co., Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: JP¥4.69 (vs JP¥5.71 in 1Q 2025)First quarter 2026 results: EPS: JP¥4.69 (down from JP¥5.71 in 1Q 2025). Revenue: JP¥400.0m (down 11% from 1Q 2025). Net income: JP¥19.0m (down 17% from 1Q 2025). Profit margin: 4.8% (down from 5.1% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 05Is PhoenixBio (TSE:6190) A Risky Investment?TSE:6190 1 Year Share Price vs Fair Value Explore PhoenixBio's Fair Values from the Community and select yours Some say...
お知らせ • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2026 Results on Aug 14, 2025PhoenixBio Co., Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • May 21Full year 2025 earnings released: JP¥110 loss per share (vs JP¥6.88 profit in FY 2024)Full year 2025 results: JP¥110 loss per share (down from JP¥6.88 profit in FY 2024). Revenue: JP¥1.54b (down 10% from FY 2024). Net loss: JP¥445.0m (down JP¥471.0m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
お知らせ • May 15PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2025.
分析記事 • Apr 07PhoenixBio Co., Ltd. (TSE:6190) Looks Inexpensive After Falling 33% But Perhaps Not Attractive EnoughPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders won't be pleased to see that the share price has had a very rough month...
New Risk • Mar 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.49b (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (JP¥1.49b market cap, or US$9.98m).
お知らせ • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025PhoenixBio Co., Ltd. announced that they will report fiscal year 2025 results on May 15, 2025
分析記事 • Feb 19PhoenixBio Co., Ltd.'s (TSE:6190) Shares Bounce 31% But Its Business Still Trails The IndustryPhoenixBio Co., Ltd. ( TSE:6190 ) shareholders would be excited to see that the share price has had a great month...
Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥6.28 loss per share (vs JP¥3.45 loss in 3Q 2024)Third quarter 2025 results: JP¥6.28 loss per share (further deteriorated from JP¥3.45 loss in 3Q 2024). Revenue: JP¥355.0m (down 21% from 3Q 2024). Net loss: JP¥26.0m (loss widened 100% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.42b market cap, or US$9.31m). Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change).
お知らせ • Dec 03PhoenixBio Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025PhoenixBio Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025
分析記事 • Nov 18PhoenixBio Co., Ltd.'s (TSE:6190) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.8x PhoenixBio Co., Ltd. ( TSE:6190 ) may be sending bullish signals at the...
New Risk • Nov 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.46b (US$9.39m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (JP¥1.46b market cap, or US$9.39m). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
お知らせ • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2025 Results on Nov 14, 2024PhoenixBio Co., Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 18First quarter 2025 earnings released: EPS: JP¥5.71 (vs JP¥11.56 in 1Q 2024)First quarter 2025 results: EPS: JP¥5.71 (down from JP¥11.56 in 1Q 2024). Revenue: JP¥449.0m (up 2.3% from 1Q 2024). Net income: JP¥23.0m (down 45% from 1Q 2024). Profit margin: 5.1% (down from 9.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥467, the stock trades at a trailing P/E ratio of 72.9x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years.
お知らせ • Jun 06PhoenixBio Co., Ltd. to Report Q1, 2025 Results on Aug 13, 2024PhoenixBio Co., Ltd. announced that they will report Q1, 2025 results on Aug 13, 2024
Reported Earnings • May 21Full year 2024 earnings released: EPS: JP¥6.88 (vs JP¥145 in FY 2023)Full year 2024 results: EPS: JP¥6.88 (down from JP¥145 in FY 2023). Revenue: JP¥1.72b (down 19% from FY 2023). Net income: JP¥26.0m (down 95% from FY 2023). Profit margin: 1.5% (down from 23% in FY 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • May 17PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024PhoenixBio Co., Ltd., Annual General Meeting, Jun 26, 2024.
お知らせ • Mar 03PhoenixBio Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024PhoenixBio Co., Ltd. announced that they will report fiscal year 2024 results on May 15, 2024
Reported Earnings • Feb 17Third quarter 2024 earnings released: JP¥3.45 loss per share (vs JP¥10.86 profit in 3Q 2023)Third quarter 2024 results: JP¥3.45 loss per share (down from JP¥10.86 profit in 3Q 2023). Revenue: JP¥447.0m (down 15% from 3Q 2023). Net loss: JP¥13.0m (down 135% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (JP¥1.92b market cap, or US$12.8m).
お知らせ • Dec 07PhoenixBio Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024PhoenixBio Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024
Reported Earnings • Nov 19Second quarter 2024 earnings released: JP¥4.05 loss per share (vs JP¥76.11 profit in 2Q 2023)Second quarter 2024 results: JP¥4.05 loss per share (down from JP¥76.11 profit in 2Q 2023). Revenue: JP¥442.0m (down 36% from 2Q 2023). Net loss: JP¥15.0m (down 106% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2024 Results on Nov 14, 2023PhoenixBio Co., Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023
Reported Earnings • Aug 17First quarter 2024 earnings released: EPS: JP¥11.56 (vs JP¥31.15 in 1Q 2023)First quarter 2024 results: EPS: JP¥11.56 (down from JP¥31.15 in 1Q 2023). Revenue: JP¥439.0m (down 1.3% from 1Q 2023). Net income: JP¥42.0m (down 59% from 1Q 2023). Profit margin: 9.6% (down from 23% in 1Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 14, 2023PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 14, 2023
Reported Earnings • May 19Full year 2023 earnings released: EPS: JP¥145 (vs JP¥117 loss in FY 2022)Full year 2023 results: EPS: JP¥145 (up from JP¥117 loss in FY 2022). Revenue: JP¥2.12b (up 60% from FY 2022). Net income: JP¥493.0m (up JP¥880.0m from FY 2022). Profit margin: 23% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: JP¥10.86 (vs JP¥9.37 loss in 3Q 2022)Third quarter 2023 results: EPS: JP¥10.86 (up from JP¥9.37 loss in 3Q 2022). Revenue: JP¥525.0m (up 77% from 3Q 2022). Net income: JP¥37.0m (up JP¥68.0m from 3Q 2022). Profit margin: 7.0% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Dec 04PhoenixBio Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023PhoenixBio Co., Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥76.11 (vs JP¥58.69 loss in 2Q 2022)Second quarter 2023 results: EPS: JP¥76.11 (up from JP¥58.69 loss in 2Q 2022). Revenue: JP¥690.0m (up 273% from 2Q 2022). Net income: JP¥253.0m (up JP¥447.0m from 2Q 2022). Profit margin: 37% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 2 highly experienced directors. 1 independent director (6 non-independent directors). Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Sep 03PhoenixBio Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022PhoenixBio Co., Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022
Reported Earnings • Aug 14First quarter 2023 earnings released: EPS: JP¥31.15 (vs JP¥19.46 in 1Q 2022)First quarter 2023 results: EPS: JP¥31.15 (up from JP¥19.46 in 1Q 2022). Revenue: JP¥445.0m (down 1.5% from 1Q 2022). Net income: JP¥103.0m (up 61% from 1Q 2022). Profit margin: 23% (up from 14% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Jun 03PhoenixBio Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022PhoenixBio Co., Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022
お知らせ • May 18PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022PhoenixBio Co., Ltd., Annual General Meeting, Jun 28, 2022.
Reported Earnings • May 17Full year 2022 earnings released: JP¥117 loss per share (vs JP¥73.60 loss in FY 2021)Full year 2022 results: JP¥117 loss per share (down from JP¥73.60 loss in FY 2021). Revenue: JP¥1.32b (up 31% from FY 2021). Net loss: JP¥387.0m (loss widened 63% from FY 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Outside Director Yoshinori Fujii was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 08PhoenixBio Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022PhoenixBio Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022
Reported Earnings • Feb 16Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥9.37 loss per share (up from JP¥24.33 loss in 3Q 2021). Revenue: JP¥296.0m (up 48% from 3Q 2021). Net loss: JP¥31.0m (loss narrowed 61% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Second quarter 2022 earnings released: JP¥58.69 loss per share (vs JP¥44.41 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥185.0m (up 33% from 2Q 2021). Net loss: JP¥194.0m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19Full year 2021 earnings released: JP¥73.60 loss per share (vs JP¥142 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: JP¥1.01b (down 23% from FY 2020). Net loss: JP¥238.0m (loss narrowed 43% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year.
お知らせ • Mar 04PhoenixBio Co., Ltd. to Report Fiscal Year 2021 Results on May 14, 2021PhoenixBio Co., Ltd. announced that they will report fiscal year 2021 results on May 14, 2021
Reported Earnings • Feb 14Third quarter 2021 earnings released: JP¥24.33 loss per share (vs JP¥9.54 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: JP¥200.0m (down 36% from 3Q 2020). Net loss: JP¥80.0m (loss widened 186% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Dec 22New 90-day low: JP¥582The company is down 20% from its price of JP¥727 on 23 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 18% over the same period.
Is New 90 Day High Low • Dec 03New 90-day low: JP¥616The company is down 9.0% from its price of JP¥679 on 04 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period.
お知らせ • Sep 06PhoenixBio Co., Ltd. to Report Q2, 2021 Results on Nov 13, 2020PhoenixBio Co., Ltd. announced that they will report Q2, 2021 results on Nov 13, 2020
お知らせ • Jun 20PhoenixBio Co., Ltd. to Report Q1, 2021 Results on Aug 12, 2020PhoenixBio Co., Ltd. announced that they will report Q1, 2021 results on Aug 12, 2020